2016年

by 腫瘍病態学分野
  1. Yamanaka R, Morii K, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tsukamoto Y, Ogura R, Natsumeda M, Aoki H, Akiyama K, Saitou T, Tamura T, Hondoh H, Kawaguchi A, Takahashi H, Fujii Y. Late relapse of primary central nervous system lymphoma. Leuk Lymphoma 58(2):475-477, 2016.
  2. Tsukamoto Y, Ohtsu N, Echizenya S, Otsuguro S, Ogura R, Natsumeda M, Isogawa M, Aoki H, Ichikawa S, Sakaitani M, Matsuda A, Maenaka K, Fujii Y, Kondo T. High-throughput drug screening identifies EUrd as a novel inhibitor against Temozolomide-resistant glioblastoma -initiating cells. Stem Cells 34(8):2016-25, 2016.
  3. Natsumeda M, Maitani K, Liu Y, Miyahara H, Kaur H, Chu Q, Zhang H, Kahlert U, Eberhart CG. Targeting Notch signaling and autophagy increases cytotoxicity in glioblastoma neurospheres. Brain Pathol 26(6):713-723, 2016.
  4. Yoshimura J, Miyahara H, Natsumeda M, Kakita A, Fujii Y. Gli3: a favorable prognostic factor for patients with medulloblastoma. Nihon Rinsho 74 Suppl7:292-297, 2016. (和)
  5. 棗田学，五十嵐博中，野村俊春，小倉良介，塚本佳広，小林勉，青木洋，岡本浩一郎，中田力，藤井幸彦．3T-MRSを用いたグリオーマのIDH変異術前評価．CI研究 37(3-4):105-110, 2016.(和)